Marinus Pharmaceuticals (NASDAQ:MRNS) Given Hold Rating at Jefferies Financial Group

Jefferies Financial Group reiterated their hold rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note released on Friday, Benzinga reports. Jefferies Financial Group currently has a $0.50 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $5.00.

MRNS has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, September 24th. Finally, LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Eight investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $6.07.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS traded up $0.11 during midday trading on Friday, reaching $0.41. The company had a trading volume of 43,511,731 shares, compared to its average volume of 1,511,061. Marinus Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $11.26. The firm has a market cap of $22.31 million, a price-to-earnings ratio of -0.15 and a beta of 1.14. The company has a fifty day simple moving average of $1.54 and a two-hundred day simple moving average of $1.61.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The business had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. During the same period in the prior year, the company posted ($0.61) earnings per share. Analysts expect that Marinus Pharmaceuticals will post -1.93 EPS for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several institutional investors have recently modified their holdings of MRNS. Avoro Capital Advisors LLC lifted its stake in Marinus Pharmaceuticals by 31.4% in the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after acquiring an additional 990,607 shares in the last quarter. Vanguard Group Inc. lifted its stake in Marinus Pharmaceuticals by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after acquiring an additional 132,689 shares in the last quarter. abrdn plc raised its stake in shares of Marinus Pharmaceuticals by 146.1% during the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after purchasing an additional 1,578,329 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $813,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $727,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.